Navigation Links
aTyr Pharma Secures $23M Financing From Top Tier Venture Investor
Date:10/26/2010

SAN DIEGO, Oct. 26 /PRNewswire/ -- aTyr Pharma, the physiocrine therapeutics company, today announced a $23 million Series C equity financing led by Domain Associates.  Domain joins existing venture investors Alta Partners, Cardinal Partners and Polaris Ventures, who also participated in the financing.  Proceeds will be used to accelerate the development of aTyr's preclinical pipeline and advance physiocrine drug candidates into clinical trials.  Physiocrines are a recently elucidated class of endogenous human proteins that function as extracellular signaling molecules in a variety of physiologic settings.  As either therapeutic proteins or as targets for antibodies, physiocrines have the potential to address a wide range of diseases, including high unmet patient needs in blood, immune, and metabolism disorders.

"Physiocrines offer a completely new set of physiologic extracellular pathways for developing novel therapeutics.  These natural human proteins function in normal and pathologic settings, yet act via mechanisms that are differentiated and potentially superior from other therapeutic approaches," said James C. Blair, Ph.D., Partner at Domain Associates.  "We believe multiple products within aTyr's portfolio offer promise for fundamentally improved patient care while achieving attractive commercial goals.  We are enthusiastic to work with aTyr's leadership team and existing syndicate to build a world class protein therapeutics enterprise."  

"Attracting investors with a successful track record in protein therapeutics further re-enforces the therapeutic promise of our new class of human proteins, physiocrines.  As the exclusive developer of physiocrine-based therapeutics, aTyr is well positioned by this recent financing to further build a strong, sustainable pipeline of innovative medicines for patients," said Jeff Watkins, Ph.D., Chief Executive Officer of aTyr Pharma.  "Our initial physiocrine program heading to the clinic, Tmax, for treating thrombocytopenia, will serve as our first proof of concept for this exciting class of protein-based therapeutics."

As part of the financing Dr. James C. Blair will serve as a Director for the company, joining current board members Mr. John Clarke, Dr. David Mack, Dr. John Mendlein, Dr. Amir Nashat, Dr. Paul Schimmel and Dr. Jeff Watkins.

About Physiocrines

Physiocrines are a new class of extracellular proteins that modulate signaling pathways in a variety of physiological processes.  Physiocrines are derived from tRNA synthetases, which function intracellularly, and thus were overlooked by genomic discovery efforts.  These endogenous human proteins have a broad range of activities and act through a variety of receptor classes, via mechanisms distinct from current pharmaceuticals, and have applications relevant to a number of therapeutic areas ranging from immunology and hematology to metabolism disorders.

About aTyr Pharma

aTyr Pharma develops biologic therapeutics based on physiocrines, and is currently focusing on developing products to improve patient care in immune, metabolic, and hematologic indications.  aTyr Pharma has established a dominant intellectual property estate surrounding physiocrine based compositions and therapeutic applications. The company's leading program, Tmax, is in preclinical development.  The privately held biotech was founded by Dr. Paul Schimmel, a leading aminoacyl tRNA synthetase scientist and biotechnology entrepreneur, and John Clarke from Cardinal Partners.  aTyr Pharma is backed by leading life sciences investors Alta Partners, Cardinal Partners, Domain Associates and Polaris Ventures. For more information please visit www.atyrpharma.com


'/>"/>
SOURCE aTyr Pharma
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Biostar Pharmaceuticals, Inc. Expands Rural Network by Over 21% in Third Quarter 2010; Brings Total Number of Locations to 8,500
2. OncoGenex Pharmaceuticals, Inc. Closes $50 Million Public Offering
3. A New BioPharma Intelligence Resource Set to Give Industry Leaders the Edge
4. Access Pharmaceuticals Files Additional IP For Cobalamin Oral Delivery Technology
5. Amylin Pharmaceuticals Announces Third Quarter Product Revenues; Quarterly Update Conference Call Canceled
6. Reportlinker Adds Downstream Processing in Biopharmaceuticals - Increased Demand for Biologics Drives Improvement in Cost -effective Purification Technologies
7. OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering
8. Lotus Pharmaceuticals Announces New Patent for Controlled-Release Diabetes Drug
9. OncoGenex Pharmaceuticals, Inc. Announces Proposed Public Offering
10. ANGIOTECH PHARMACEUTICALS ANNOUNCES CONFERENCE CALL AND WEBCAST
11. Biopharma Leaders to Reveal Successful Strategies for China, India at the PharmAsia Summit in San Francisco
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... ... April 27, 2016 , ... Most consumers ... with fingerprint recognition for secure access, voice recognition for hands-free communication, and facial ... are interacting with biometrics technology today. But if they asked Joey Pritikin, ...
(Date:4/27/2016)... ... April 27, 2016 , ... The Board of ... appointment of John Tilton as Chief Commercial Officer.  Mr. Tilton joined Biohaven from ... founding commercial leaders responsible for the commercialization of multiple orphan drug indications. ...
(Date:4/27/2016)... ... April 27, 2016 , ... A compact PET scanner ... and MRI (Magnetic Resonance Imaging) in existing third-party MRI systems. PET and MRI ... small animal subjects. Simultaneous PET/MRI imaging offers a solution to many challenges that ...
(Date:4/27/2016)... -- MedDay, a biotechnology company focused on the ... Catherine Moukheibir as Chairman of its Board of Directors. ... Garaud , who contributed to the rapid development of the ... Catherine started her career in strategy consulting and investment banking ... .  She held C-Suite level roles in some of ...
Breaking Biology Technology:
(Date:4/15/2016)... -- A new partnership announced today will help life ... a fraction of the time it takes today, ... insurance policies to consumers without requiring inconvenient and ... rapid testing (A1C, Cotinine and HIV) and higi,s ... pulse, BMI, and activity data) available at local ...
(Date:4/14/2016)... BioCatch ™, the global ... the appointment of Eyal Goldwerger as CEO. ... Goldwerger,s leadership appointment comes at a time of significant ... of its platform at several of the world,s largest ... unique cognitive and physiological factors, is a winner of ...
(Date:3/31/2016)... March 31, 2016   ... or the "Company") LegacyXChange is excited to ... its soon to be launched online site for trading ... ) will also provide potential shareholders a sense ... technology to an industry that is notorious for fraud. ...
Breaking Biology News(10 mins):